HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis].

AbstractOBJECTIVE:
To develop recommendations for the diagnosis, management and treatment of lupus nephritis in Brazil.
METHOD:
Extensive literature review with a selection of papers based on the strength of scientific evidence and opinion of the Commission on Systemic Lupus Erythematosus members, Brazilian Society of Rheumatology.
RESULTS AND CONCLUSIONS:
1) Renal biopsy should be performed whenever possible and if this procedure is indicated; and, when the procedure is not possible, the treatment should be guided with the inference of histologic class. 2) Ideally, measures and precautions should be implemented before starting treatment, with emphasis on attention to the risk of infection. 3) Risks and benefits of treatment should be shared with the patient and his/her family. 4) The use of hydroxychloroquine (preferably) or chloroquine diphosphate is recommended for all patients (unless contraindicated) during induction and maintenance phases. 5) The evaluation of the effectiveness of treatment should be made with objective criteria of response (complete remission/partial remission/refractoriness). 6) ACE inhibitors and/or ARBs are recommended as antiproteinuric agents for all patients (unless contraindicated). 7) The identification of clinical and/or laboratory signs suggestive of proliferative or membranous glomerulonephritis should indicate an immediate implementation of specific therapy, including steroids and an immunosuppressive agent, even though histological confirmation is not possible. 8) Immunosuppressives must be used during at least 36 months, but these medications can be kept for longer periods. Its discontinuation should only be done when the patient achieve and maintain a sustained and complete remission. 9) Lupus nephritis should be considered as refractory when a full or partial remission is not achieved after 12 months of an appropriate treatment, when a new renal biopsy should be considered to assist in identifying the cause of refractoriness and in the therapeutic decision.
AuthorsEvandro Mendes Klumb, Clovis Artur Almeida Silva, Cristina Costa Duarte Lanna, Emilia Inoue Sato, Eduardo Ferreira Borba, João Carlos Tavares Brenol, Elisa Martins das Neves de Albuquerque, Odirlei Andre Monticielo, Lilian Tereza Lavras Costallat, Luiz Carlos Latorre, Maria de Fátima Lobato da Cunha Sauma, Eloisa Silva Dutra de Oliveira Bonfá, Francinne Machado Ribeiro
JournalRevista brasileira de reumatologia (Rev Bras Reumatol) 2015 Jan-Feb Vol. 55 Issue 1 Pg. 1-21 ISSN: 1809-4570 [Electronic] Brazil
Vernacular TitleConsenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica.
PMID25595733 (Publication Type: Consensus Development Conference, Journal Article, Practice Guideline)
CopyrightCopyright © 2014 Elsevier Editora Ltda. All rights reserved.
Topics
  • Biopsy
  • Brazil
  • Disease Progression
  • Humans
  • Lupus Nephritis (diagnosis, therapy)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: